Viroclinics-DDL and Infinity BiologiX deepen their partnership
The two companies bring their existing partnership to the next level by developing customized services to assist pharma, biotech and governmental clients with clinical diagnostics and global logistical services.
Infinity BiologiX (IBX) is a market-disrupting next-generation central laboratory. It collaborates with, and provides services to researchers and organizations in both the public and private sectors, including sample collection and processing, storage and analytical services, and scientific and technical support in both the research and clinical arenas. The company was previously RUCDR Infinite Biologics before spinning off from Rutgers University-New Brunswick in August 2020 and was the first to receive FDA EAU for Saliva based COVID-19 diagnostics test and at home collection.
For more information please visit www.ibx.bio
Viroclinics-DDL is a global leading virology contract research organization, serving the biopharmaceutical community with a broad range of preclinical research, clinical diagnostic, assay development and clinical trial logistic services. Viroclinics-DDL’s extensive experience with clinical and preclinical studies for viruses, including its specialty in respiratory viruses, puts the company at the forefront in supporting the development of vaccines, antibodies and antiviral compounds targeting viral infectious diseases. Our in-house state of the art preclinical and clinical BSL-2 and BSL-3 laboratories allow for complex experiments with highly pathogenic organisms. Viroclinics-DDL is based in The Netherlands and employs more than 270 well-trained, dedicated scientists and technical experts.
For more information: www.viroclinics.com and www.ddl.nl
Marketing & Communications Manager
P: +31 88 668 4787